Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

<p>Abstract</p> <p>It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for treating hyperglycemia in patients...

Full description

Bibliographic Details
Main Authors: Yushmanova Irina, Nicewarner Dawn, Han Jenny, Ratner Robert, Hoogwerf Byron J, Shen Larry
Format: Article
Language:English
Published: BMC 2011-03-01
Series:Cardiovascular Diabetology
Subjects:
GLP-1 receptor agonist
diabetes
cardiovascular safety
Online Access:http://www.cardiab.com/content/10/1/22

Internet

http://www.cardiab.com/content/10/1/22

Similar Items